BMPR2 and pulmonary arterial hypertension: Pulmonary vSMCs carrying mutation of bone morphogenetic protein type-2 receptor (BMPR2), which accounts for 70% of the heritable form of PAH, also predisposes vSMC to switch to a more synthetic phenotype, resulting in reduced expression of contractile proteins and increased proliferation and migration[14–16].